United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

city medical store - sole proprietorship l.l.c ireland - 1 glass vial (30 ml) - infusion - 300 mg/30 ml (10 mg/ml) - malignant disease , immumosuppression-immunosuppressants

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

hetero laboratories limited, india - dolutegravir, lamivudine , tenofovir disoproxil fumarate tablets 50mg/300mg/300mg - oral tablet - 50/300/300

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

hetero laboratories limited, india - dolutegravir, lamivudine , tenofovir disoproxil fumarate tablets 50mg/300mg/300mg - oral tablet - 50/300/300

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

lupin limited, india - dolutegravir, lamivudine , tenofovir disoproxil fumarate tablets 50mg/300mg/300mg - tablet, film-coated - 50/300/300

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 30 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 60 microgram; hpv type 18 l1 protein, quantity: 40 microgram; hpv type 31 l1 protein, quantity: 20 microgram; hpv type 33 l1 protein, quantity: 20 microgram; hpv type 45 l1 protein, quantity: 20 microgram; hpv type 52 l1 protein, quantity: 20 microgram; hpv type 58 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: polysorbate 80; aluminium; histidine; sodium chloride; borax; water for injections - gardasil 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,gardasil 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). immunogenicity studies of gardasil 9 have been conducted relating to females over 26 years of age (see section 5.1 clinical trials for gardasil 9).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 30 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 60 microgram; hpv type 18 l1 protein, quantity: 40 microgram; hpv type 31 l1 protein, quantity: 20 microgram; hpv type 33 l1 protein, quantity: 20 microgram; hpv type 45 l1 protein, quantity: 20 microgram; hpv type 52 l1 protein, quantity: 20 microgram; hpv type 58 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: sodium chloride; histidine; borax; aluminium; water for injections; polysorbate 80 - gardasil 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,gardasil 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). immunogenicity studies of gardasil 9 have been conducted relating to females over 26 years of age (see section 5.1 clinical trials for gardasil 9).

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 623 mg/ml equivalent to iodine 300 mg/ml - solution for infusion - 300 mg/ml - active: iopromide 623 mg/ml equivalent to iodine 300 mg/ml excipient: hydrochloric acid as 10% solution sodium calcium edetate trometamol water for injection - for intravascular use and use in body cavities. contrast enhancement in computerised tomography (ct), arteriography and venography, intravenous/intra-arterial digital subtraction angiography (dsa), intravenous urography, use for ercp, arthrography and examination of other body cavities. ultravist 240: also for intrathecal use. ultravist 370: especially for angiocardiography. ultravist 300/370: not for intrathecal use.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الرام للصناعات الدوائية - ram pharmaceutical industries co. ltd. - paracetamol 33.3 mg/5ml, oxomemazine (as hcl) 1.65 mg/5ml, guaifenesin 33.3 mg/5ml, sodium benzoate 33.3 mg/5ml - 33.3 mg/5ml, (as hcl) 1.65 mg/5ml, 33.3 mg/5ml, 33.3 mg/5ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الرام للصناعات الدوائية - ram pharmaceutical industries co. ltd. - paracetamol 33.3 mg/5ml, oxomemazine (as hcl) 1.65 mg/5ml, guaifenesin 33.3 mg/5ml, sodium benzoate 33.3 mg/5ml - 33.3 mg/5ml, (as hcl) 1.65 mg/5ml, 33.3 mg/5ml, 33.3 mg/5ml

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الرام للصناعات الدوائية - ram pharmaceutical industries co. ltd. - paracetamol 33.3 mg/5ml, oxomemazine (as hcl) 1.65 mg/5ml, guaifenesin 33.3 mg/5ml, sodium benzoate 33.3 mg/5ml - 33.3 mg/5ml, (as hcl) 1.65 mg/5ml, 33.3 mg/5ml, 33.3 mg/5ml